The Limerston Capital-backed firm has acquired the laboratory group in the US following its first moves into the German market.
Limerston Capital-backed Cormica, a medical device and pharmaceuticals testing group, continues its expansion with the acquisition of Focus Laboratories, which operates facilities in Allentown, Pennsylvania, and Palm Harbor, Florida.
Financial terms have not been disclosed.
Founded in 1996, Focus Laboratories specialises in microbiological testing, including rapid microbiology and consulting for the pharmaceutical, biotech and medical device sectors. Cormica said that the acquisition will enable the business to leverage Cormica’s broader capabilities and resources, fostering organic growth and innovation.
The acquisition follows Cormica’s acquisition of TPM Laboratories last year – its first in the US.
“Cormica’s acquisition of Focus Laboratories supports our strategy to expand into high-growth markets within the life sciences, reinforcing our position as a leading operator in the sector,” said João Rosa, founding partner of Limerston Capital. “This partnership offers significant synergies, enabling us to address a wider array of client needs, from micro to analytical chemistry, and vice versa,” he added.
First foothold
The acquisition in the US follows the firm’s first takeover in Germany in mid-January.
It completed its acquisition of Zwisler Laboratorium, a provider of laboratory services headquartered in Reichenau.
Founded in 2001, Zwisler Laboratorium operates from a facility in southern Germany and delivers tailored services to pharmaceutical, biotech, packaging and medical device industries across Europe. The laboratory specialises in in-vitro pyrogen tests, IFU, reprocessing validation, environmental monitoring, microbiological integrity tests, and bespoke consulting services to support clients in meeting regulatory requirements. It has also developed in-vitro testing options to reduce in-vivo testing.
“Germany is a key growth area for Cormica and this is an exciting first foothold in the market,” said Jane Grewar, senior operating partner at Limerston Capital.
Cormica helps life science manufacturers and medtech innovators to launch their products more rapidly, securely, and across more markets. The group has approximately 250 employees based across laboratory facilities in the UK, US and Germany.
